Program
elenestinib
Also written as “Elenestinib” and “BLU-263”.
In Sanofi's pipeline, D816V-mutated KIT inhibitor
. Its studies are mostly in Mastocytosis, Systemic, led by Sanofi.
Furthest: phase 3, since May 17, 20213 company-led studies, 1 open or runningNext primary completion: Sep 30, 2032 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sanofi | 31 open or running | phase 3since May 17, 2021 | May 17, 2021 | Sep 30, 2032phase 3 · NCT04910685 |
- Named in Sanofi’s own pipeline as
elenestinib
, phase 3, as of Sep 30, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 17, 2021First study: phase 3 study in Mastocytosis, SystemicFirst studyNCT04910685 · 534 planned · United States, Argentina, Australia and more
- Nov 2, 2022Phase 1 study in Mastocytosis, SystemicNCT05609942 · 9 enrolled · United States, Belgium, France and more
- Jan 29, 2026Phase 1 study in Healthy ParticipantsNCT07388511 · 20 enrolled · United States
Ahead
- Sep 30, 2032Primary completion: phase 3 study in Mastocytosis, SystemicNCT04910685
TargetBeta
“D816V-mutated KIT inhibitor”the company's pipeline, read by Claude · source
“An orally bioavailable protein tyrosine kinase inhibitor of the mutated form of the tumor-associated antigen (TAA) mast/stem cell factor receptor c-Kit (SCFR), D816V, with potential antineoplastic activity. Upon oral administration, elenestinib binds to and inhibits the specific c-Kit mutant D816…”NCIt, read by Claude
“An orally bioavailable protein tyrosine kinase inhibitor of the mutated form of the tumor-associated antigen (TAA) mast/stem cell factor receptor c-Kit (SCFR), D816V, ”NCIt, by rule
Other programs on KIT
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| imatinibrule | Novartis | phase 4 | 70 |
| regorafenibrule | Bayer | phase 4 | 40 |
| Avapritinibrule | Sanofi | phase 4 | 10 |
| anlotinibrule | Sino Biopharmaceutical | phase 3 | 40 |
| masitinibrule | AB Science | phase 3 | 38 |
| quizartinibrule | Daiichi Sankyo | phase 3 | 22 |
| ripretinibrule | Ono Pharmaceutical | phase 3 | 9 |
| velzatinib | GlaxoSmithKline | phase 3 | 8 |
| seralutinibrule | gb002-inc-a-wholly-owned-subsidiary-of-gossamer-bio-inc | phase 3 | 8 |
| NB-003rule | ningbo-newbay-technology-development-co-ltd | phase 3 | 2 |
| briquilimabrule | jasper-therapeutics-inc | phase 2 | 7 |
| BLU-808 | Sanofi | phase 2 | 3 |
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07388511Healthy Participants · United States | 1 | Completed | Apr 2, 2026 | 20 |
| NCT05609942Mastocytosis, Systemic · United States, Belgium, France and more | 1 | Terminated | Jan 14, 2025 | 9 |
| NCT04910685Mastocytosis, Systemic · United States, Argentina, Australia and more | 3 | Recruiting | Sep 30, 2032 | 534 |
How it is read
Names in the registry
- “Elenestinib”, 2 entries
- “BLU-263”, 1 entry
Conditions, from the studies’ own filings
- Mastocytosis, Systemic, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.